Production and radiochemical purity of 177Lu-PSMA-617 for clinical trial

被引：0
|
作者：
Asad, Ali [1 ]
Scharli, Rainer [2 ]
Morandeau, Laurence [1 ]
Price, Roger [3 ]
机构：
[1] Sir Charles Gairdner Hosp, Nedlands, WA, Australia
[2] Univ Western Australia, Nedlands, WA, Australia
[3] Sir Charles Gairdner Hosp, Med Technol & Phys, Nedlands, WA, Australia
来源：
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS | 2019年 / 62卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
P-358
引用
收藏
页码：S527 / S527
页数：1
相关论文
共 50 条
  • [21] Formulation of clinical-scale 177Lu-PSMA-617: From laboratory to clinics
    Das, Tapas
    Guleria, Mohini
    Banerjee, Sharmila
    NUCLEAR MEDICINE AND BIOLOGY, 2016, 43 (12) : 835 - 836
  • [22] Renal Function after Radioligand Treatment with 177Lu-PSMA-617
    Ngoc, Christina Nguyen
    Happel, Christian
    Davis, Karen
    Groener, Daniel
    Mader, Nicolai
    Mandel, Philipp
    Tselis, Nikolaos
    Gruenwald, Frank
    Sabet, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [23] The 177Lu-PSMA-617 (Pluvicto) Supply Problem Will Be Solved by Competition
    Czernin, Johannes
    Calais, Jeremie
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (03) : 343 - 343
  • [24] Clinical Implementation of 177Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges
    Ravi, Praful
    Whelpley, Bridget
    Kelly, Emma
    Wolanski, Andrew
    Ritzer, Jolivette
    Robertson, Matthew
    Shah, Hina
    Morgans, Alicia K.
    Wei, Xiao X.
    Sunkara, Rajitha
    Pomerantz, Mark
    Taplin, Mary -Ellen
    Kilbridge, Kerry L.
    Choudhury, Atish D.
    Jacene, Heather
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (03) : 349 - 350
  • [25] Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions
    Wang, Jingnan
    Zang, Jie
    Wang, Hao
    Liu, Qingxing
    Li, Fang
    Lin, Yansong
    Huo, Li
    Jacobson, Orit
    Niu, Gang
    Fan, Xinrong
    Zhu, Zhaohui
    Chen, Xiaoyuan
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (06) : 431 - 438
  • [26] Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial
    Nauseef, Jones Trevor
    Thomas, Charlene
    Sun, Michael
    Jacobs, Nicole
    Fajardo, Andres Ricaurte
    Ruder, Sam
    Fernandez, Escarleth
    Davidson, Zachary
    Patel, Amie
    Sartor, A. Oliver
    Vallabhajosula, Shankar
    Molina, Ana
    Sternberg, Cora N.
    Nanus, David M.
    Castellanos, Sandra Huicochea
    Osborne, Joseph
    Bander, Neil H.
    Perk, Timothy
    Tagawa, Scott
    CANCER RESEARCH, 2024, 84 (07)
  • [27] Prostate Cancer Treatment: 177Lu-PSMA-617 Considerations, Concepts, and Limitations
    Sartor, Oliver
    Herrmann, Ken
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (06) : 823 - 829
  • [28] VISION trial: 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer
    Rohith, Gorrepati
    INDIAN JOURNAL OF UROLOGY, 2021, 37 (04) : 372 - 373
  • [29] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Kambiz Rahbar
    Martin Bögemann
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 166 - 167
  • [30] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Rahbar, Kambiz
    Boegemann, Martin
    Ahmadzadehfar, Hojjat
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 166 - 167
12345